Performance Comparison Between Masimo W… | Clinical Trial

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Primary location

Human Pharmacology and Physiology Laboratory (HPPL) - Duke University Medical Center

Durham, North Carolina, 27705, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject is 18 to 55 years of age.
Subject is American Society Anesthesiologist status 1 (ASA I)
Subject has a BMI between 18 and 35.
Subject is able to read and communicate in English and understands the study and the risks involved.

Exclusion criteria

Subject is currently taking any medications which in the opinion of the principal investigator would not be suitable for participation in the study.
Subject is wearing nail polish that cannot be removed, gel nails, and/or acrylic nails that can interfere with study device's placement.
Participants with conditions or skin abnormalities at or around site of sensor placement that could affect the placement on the sensor or prevent monitoring of physiological parameters during the study, such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown.
Subject has participated in an investigational drug study within one month prior to the start of the study.
Subject has failed the Allen's Test to confirm patency of the collateral artery.
Subject is female with a positive pregnancy test, or is female and is unwilling to use effective birth control between the time of screening and study termination.
Subject has a positive urine cotinine or drug test.
Subject has a reported allergy to Lidocaine.
Subject has clinically significant anemia or other hemoglobinopathy.
Subject has a room air saturation of less than 95% by pulse oximetry.
Subject has a clinically significant abnormal EKG.
Subject has a clinically significant abnormal pulmonary function test via spirometry.
Subject is intolerant to a breathing mask apparatus.
Subject has a COHb greater than 3%, or MetHb greater than 2% verified by laboratory co-oximeter.
Subject has another condition, which in the opinion of the principal investigator would not be suitable for participation in the study.
Subject is unwilling or unable to provide informed consent or comply with the study procedures.

Treatment and study plan

Masimo W1™ and Apple Watch Series 8

Device

Noninvasive wearable health monitoring device

Primary outcomes

Accuracy of Masimo W1™ and Apple Watch Series 8 in Determining SpO2 (Oxygen Saturation) Values in Subjects During Desaturation

Time frame: 1-6 hours

Accuracy will be determined by comparing Masimo W1™ SpO2 measurements and Apple Watch Series 8 SpO2 measurements with FDA-cleared pulse oximetry device SpO2 measurements and calculating the Arithmetic root mean square (ARMS) value. All values presented below for SpO2 (Bias, Precision and ARMS) are in units of %.

The pairwise samples consist of paired SpO2 timing measurements from both the reference sensor, Masimo W1, and the Apple Watch.
Successful Read Rate for Motion Conditions Under Slow Desaturation for Masimo W1™ and Apple Watch Series 8

Time frame: 1-6 hours

This analysis examines the successful read rates for motion conditions during slow desaturation events for the Masimo W1™ and Apple Watch Series 8. The motion condition consists of a combined value representing three types of simulated motion: drinking, scratching the nose, and checking the time.

Successful Read Rate = 1 - No Read Rate (Nf / Nspotcheck) x 100 (%) Nf = Number of Reads without Valid SpO2 Nspotcheck = Number of All Spot Checks
Detection Rate of Fast Desaturation Events Under Various Conditions for Masimo W1™ and Apple Watch Series 8

Time frame: 1-6 hours

Comparison of the detection rate of fast desaturation events under different conditions for the Masimo W1™ and Apple Watch Series 8. The first condition involves no motion, with the palm facing down and the Apple Watch in sleep mode, while the second condition involves no motion, with the palm facing sideways and manual spot checks performed on the Apple Watch. The goal is to evaluate the performance of both devices in detecting desaturation events under these varying circumstances.

Detection Rate = (Nt / Ndesat) x 100 (%) Nt = Number of Detected Event by Test Device

All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Masimo W1™ and Apple Watch Series 8.

Ndesat = Number of All Valid Fast Desaturation Events by Reference SpO2

Sponsors and collaborators

Lead sponsor

Masimo Corporation

Industry

Registry information

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Aug 1, 2023
Registry last updated: Apr 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed